1. Home
  2. MGNI vs PHVS Comparison

MGNI vs PHVS Comparison

Compare MGNI & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magnite Inc.

MGNI

Magnite Inc.

HOLD

Current Price

$12.89

Market Cap

1.9B

Sector

Technology

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$29.56

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGNI
PHVS
Founded
2007
2015
Country
United States
Switzerland
Employees
514
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
MGNI
PHVS
Price
$12.89
$29.56
Analyst Decision
Strong Buy
Buy
Analyst Count
9
11
Target Price
$25.22
$41.82
AVG Volume (30 Days)
1.8M
205.9K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
493.75
N/A
EPS
0.95
N/A
Revenue
$156,414,000.00
N/A
Revenue This Year
$6.28
N/A
Revenue Next Year
$9.76
N/A
P/E Ratio
$13.72
N/A
Revenue Growth
25.45
N/A
52 Week Low
$10.82
$15.51
52 Week High
$26.65
$30.24

Technical Indicators

Market Signals
Indicator
MGNI
PHVS
Relative Strength Index (RSI) 51.82 58.51
Support Level $11.07 $24.73
Resistance Level $14.30 N/A
Average True Range (ATR) 0.58 1.44
MACD 0.02 0.02
Stochastic Oscillator 52.58 89.53

Price Performance

Historical Comparison
MGNI
PHVS

About MGNI Magnite Inc.

Magnite is a supply-side advertising platform that provides technology and yield management solutions to content publishers, enabling them to monetize their digital advertising inventory. Magnite receives a percentage of all advertising inventory that it sells. 43% of Magnite's revenue is derived from connected television, or CTV, streaming platforms, 40% from mobile applications, and the remainder from general websites. Beyond the typical monetization responsibilities inherent to an SSP, Magnite also provides upstream advertising servers to CTV publishers, allowing them to have granular control over direct-sold, programmatic guaranteed, and open-auction logic. Magnite competes with other independent SSPs, supply path optimization solutions, and closed ecosystems like Meta.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: